3.316EUR+0.06%Mkt Cap: 85.77M $P/E: —Today
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi tha…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
| Headline | Source | Time |
|---|---|---|
This week | ||
Older | ||
LLyon Décideurs | ||
 What AbbVie (ABBV)'s Restructured OSE Immunology Partnership Means For Shareholders Earlier in December 2025, OSE Immunotherapeutics amended its partnership with AbbVie over the inflammatory disease candidate ABBV-230, with OSE taking back control of preclinical and Phase 1 work, at its own funding risk, while AbbVie kept exclusive rights to later-stage development and commercialization on unchanged economic terms. The revised ABBV-230 arrangement underlines AbbVie’s willingness to lean on partners’ early-stage immunology expertise while reserving control of potential... | ||